TitleElucidating the transcriptional program of feline injection-site sarcoma using a cross-species mRNA-sequencing approach.
Publication TypeJournal Article
Year of Publication2019
AuthorsWei, Q, Ramsey, SA, Larson, MK, Berlow, NE, Ochola, D, Shiprack, C, Kashyap, A, Séguin, B, Keller, C, Löhr, CV
JournalBMC Cancer
Date Published2019 Apr 04
KeywordsAnimals, Antineoplastic Agents, Cat Diseases, Cats, Cell Line, Tumor, DNA Copy Number Variations, Dogs, Gene Expression Profiling, Genes, Tumor Suppressor, High-Throughput Nucleotide Sequencing, Humans, Injection Site Reaction, Male, Oncogenes, Primary Cell Culture, RNA, Messenger, Sarcoma, Sequence Analysis, RNA, Species Specificity, Tumor Cells, Cultured

BACKGROUND: Feline injection-site sarcoma (FISS), an aggressive iatrogenic subcutaneous malignancy, is challenging to manage clinically and little is known about the molecular basis of its pathogenesis. Tumor transcriptome profiling has proved valuable for gaining insights into the molecular basis of cancers and for identifying new therapeutic targets. Here, we report the first study of the FISS transcriptome and the first cross-species comparison of the FISS transcriptome with those of anatomically similar soft-tissue sarcomas in dogs and humans.

METHODS: Using high-throughput short-read paired-end sequencing, we comparatively profiled FISS tumors vs. normal tissue samples as well as cultured FISS-derived cell lines vs. skin-derived fibroblasts. We analyzed the mRNA-seq data to compare cancer/normal gene expression level, identify biological processes and molecular pathways that are associated with the pathogenesis of FISS, and identify multimegabase genomic regions of potential somatic copy number alteration (SCNA) in FISS. We additionally conducted cross-species analyses to compare the transcriptome of FISS to those of soft-tissue sarcomas in dogs and humans, at the level of cancer/normal gene expression ratios.

RESULTS: We found: (1) substantial differential expression biases in feline orthologs of human oncogenes and tumor suppressor genes suggesting conserved functions in FISS; (2) a genomic region with recurrent SCNA in human sarcomas that is syntenic to a feline genomic region of probable SCNA in FISS; and (3) significant overlap of the pattern of transcriptional alterations in FISS with the patterns of transcriptional alterations in soft-tissue sarcomas in humans and in dogs. We demonstrated that a protein, BarH-like homeobox 1 (BARX1), has increased expression in FISS cells at the protein level. We identified 11 drugs and four target proteins as potential new therapies for FISS, and validated that one of them (GSK-1059615) inhibits growth of FISS-derived cells in vitro.

CONCLUSIONS: (1) Window-based analysis of mRNA-seq data can uncover SCNAs. (2) The transcriptome of FISS-derived cells is highly consistent with that of FISS tumors. (3) FISS is highly similar to soft-tissue sarcomas in dogs and humans, at the level of gene expression. This work underscores the potential utility of comparative oncology in improving understanding and treatment of FISS.

Alternate JournalBMC Cancer
PubMed ID30947707
PubMed Central IDPMC6449919
Grant ListP01 CA090890 / CA / NCI NIH HHS / United States
P01CA090890-06A2 / / National Cancer Institute /
Research Grant / / Oregon State University College of Veterinary Medicine /